BRPI0919342A2 - derivados do isoxazol [4,5] piridin-3-il-piperazina, seu processo de preparação, seu medicamento e seu uso - Google Patents

derivados do isoxazol [4,5] piridin-3-il-piperazina, seu processo de preparação, seu medicamento e seu uso

Info

Publication number
BRPI0919342A2
BRPI0919342A2 BRPI0919342A BRPI0919342A BRPI0919342A2 BR PI0919342 A2 BRPI0919342 A2 BR PI0919342A2 BR PI0919342 A BRPI0919342 A BR PI0919342A BR PI0919342 A BRPI0919342 A BR PI0919342A BR PI0919342 A2 BRPI0919342 A2 BR PI0919342A2
Authority
BR
Brazil
Prior art keywords
isoxazole
pyridin
medicine
preparation process
piperazine derivatives
Prior art date
Application number
BRPI0919342A
Other languages
English (en)
Inventor
George Jaeschke
Luca Gobbi
Lucinda Steward
Rosa Maria Rodriguez Sarmiento
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0919342A2 publication Critical patent/BRPI0919342A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0919342A 2008-09-23 2009-09-15 derivados do isoxazol [4,5] piridin-3-il-piperazina, seu processo de preparação, seu medicamento e seu uso BRPI0919342A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164904 2008-09-23
PCT/EP2009/061965 WO2010034656A1 (en) 2008-09-23 2009-09-15 Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors

Publications (1)

Publication Number Publication Date
BRPI0919342A2 true BRPI0919342A2 (pt) 2015-12-29

Family

ID=41397376

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919342A BRPI0919342A2 (pt) 2008-09-23 2009-09-15 derivados do isoxazol [4,5] piridin-3-il-piperazina, seu processo de preparação, seu medicamento e seu uso

Country Status (11)

Country Link
US (1) US7825123B2 (pt)
EP (1) EP2337783A1 (pt)
JP (1) JP2012502948A (pt)
KR (1) KR20110076944A (pt)
CN (1) CN102164927A (pt)
AU (1) AU2009296055A1 (pt)
BR (1) BRPI0919342A2 (pt)
CA (1) CA2737252A1 (pt)
IL (1) IL211565A0 (pt)
MX (1) MX2011002755A (pt)
WO (1) WO2010034656A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2344482B1 (en) * 2008-09-23 2012-08-15 F. Hoffmann-La Roche AG Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors
US8586579B2 (en) * 2010-06-21 2013-11-19 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8470828B2 (en) 2010-07-06 2013-06-25 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8877778B2 (en) 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds
AU2015270723A1 (en) * 2014-06-03 2016-11-17 F. Hoffmann-La Roche Ag Peptides as oxytocin agonists
CR20160562A (es) * 2014-06-06 2017-01-06 Hoffmann La Roche Péptidos como agonistas de la oxitocina
WO2017045599A1 (zh) * 2015-09-15 2017-03-23 浙江京新药业股份有限公司 环己烷衍生物或其立体异构体或盐及其制备与应用
CN106518841B (zh) 2015-09-15 2019-03-05 浙江京新药业股份有限公司 环己烷衍生物或其立体异构体或盐及其制备与应用
WO2018021447A1 (ja) 2016-07-28 2018-02-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
CA3089498A1 (en) 2018-01-26 2019-08-01 Shionogi & Co., Ltd. Condensed ring compounds having dopamine d3 receptor antagonistic effect

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ230045A (en) * 1988-08-05 1990-11-27 Janssen Pharmaceutica Nv 3-piperazinylbenzazole derivatives and pharmaceutical compositions
HUP9802492A3 (en) * 1995-06-06 1999-10-28 Hoechst Marion Roussel Inc Cin Benzisoxazole and indazole derivatives as antipsychotic agents, process for their preparation and pharmaceutical compositions containing the same
FR2749304B1 (fr) * 1996-06-04 1998-06-26 Adir Nouveaux derives du 3-(piperid-4-yl)1,2-benzisoxazole et du 3-(piperazin-4-yl)1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
JP5502733B2 (ja) * 2007-07-26 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ２ａ及びｄ３受容体の二重のモジュレーター
JP5367824B2 (ja) * 2008-09-22 2013-12-11 エフ．ホフマン−ラ ロシュ アーゲー ピペラジンｄ３及び５−ｈｔ２ａ受容体調節薬
EP2344482B1 (en) * 2008-09-23 2012-08-15 F. Hoffmann-La Roche AG Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors

Also Published As

Publication number Publication date
KR20110076944A (ko) 2011-07-06
JP2012502948A (ja) 2012-02-02
WO2010034656A1 (en) 2010-04-01
EP2337783A1 (en) 2011-06-29
MX2011002755A (es) 2011-04-07
CN102164927A (zh) 2011-08-24
AU2009296055A1 (en) 2010-04-01
US7825123B2 (en) 2010-11-02
IL211565A0 (en) 2011-05-31
US20100075981A1 (en) 2010-03-25
CA2737252A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
BRPI0919342A2 (pt) derivados do isoxazol [4,5] piridin-3-il-piperazina, seu processo de preparação, seu medicamento e seu uso
BRPI1009481A2 (pt) compostos de 2-acetamido-5-aril-1,2,4-triazolonas substituídas, seu processo de preparação, seu uso e medicamento compreendendo os mesmos
BR112012006404A2 (pt) derivados de di-hidropteridinona, processo de preparação e uso farmacêutico dos mesmos
BRPI0924427A2 (pt) composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
BRPI0905663A2 (pt) "emulsão estável, processo de preparação da emulsão estável e uso emulsão"
BRPI0812851A2 (pt) Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
HUS1700034I1 (hu) Izoxazolin-származékok és peszticidként történõ alkalmazásuk
BRPI0815606A2 (pt) Derivados de 6-triazol piridazina - sulfanil benzotiazol e benzimidazol, o respectivo processo de preparo, a respectiva aplicação a título de medicamentos, composições farmacêuticas e utilização, notadamente como inibidores de met.
BRPI1006162A2 (pt) "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
BRPI0911594A2 (pt) di-hidropirazolonas substistuídas, seu processo de preparação e seu uso, bem como medicamentos
BRPI0721148A2 (pt) Nanopartículas magnéticas para aplicação em hipertermia, preparação destas e uso de construtos apresentando aplicação farmacológica.
BRPI0813455A2 (pt) Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado.
BRPI1008045A2 (pt) derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
PT2590976E (pt) Derivados da imidazopiridina, seu processo de preparação e sua utilização terapêutica
BRPI0811865A2 (pt) Derivados heterocíclicos pirrolo-nitrogenados, a preparação e o uso farmacêutico dos mesmos
BRPI0813011A2 (pt) Formulação injetável aquosa estéril, processo de preparação da mesma e sua utilização
BRPI0820787A2 (pt) Processo de fiação de peuapm, fios de múltiplos filamentos de peuapm produzidos e o seu uso
BRPI0924183A2 (pt) inibidores de proteína quinase, formas cristalinas, formulações farmacêuticas e uso
FR2911604B1 (fr) Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
BRPI0822946A2 (pt) Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida
BRPI0919807A2 (pt) compostos nitrogenosos heterocíclicos , sua preparação e seu uso como medicamentos antibacterianos
BRPI0813427A2 (pt) Composto, uso do mesmo, método para tratar a infecção bacteriana em um animal de sangue quente, composição farmacêutica, e, processo para a preparação de um composto.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2376 DE 19-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.